A thiazolidinedione-statin combo reduced the levels of high-sensitivity C-reactive protein and improved the levels of fasting glucose and anti-inflammatory hormone adiponectin in participants compared with those who received a statin-placebo combo, experts reported at the annual meeting of the American Society of Hypertension. The findings suggest that the combination may curb systemic inflammation and onset of diabetes in high-risk patients, researchers added.

Related Summaries